<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01652560</url>
  </required_header>
  <id_info>
    <org_study_id>QTDS-01</org_study_id>
    <nct_id>NCT01652560</nct_id>
  </id_info>
  <brief_title>Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy</brief_title>
  <acronym>BIBC</acronym>
  <official_title>Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LiNanlin,Ph.D, Chief Physician,Clinical Professor</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      - The purpose of this study is to evaluate the efficacy and safety of the application of
      bevacizumab combined neoadjuvant chemotherapy in HER2-negative breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>From enrollment to disease progression</time_frame>
    <description>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall response</measure>
    <time_frame>From enrollment to disease progression</time_frame>
    <description>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Bevacizumab</condition>
  <condition>Neoadjuvant Chemotherapy</condition>
  <condition>Molecular Targeted Therapy</condition>
  <arm_group>
    <arm_group_label>bevacizumab combined neoadjuvant chemotherapy</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>The patients will be treated with Avastin combined neoadjuvant chemotherapy</description>
    <arm_group_label>bevacizumab combined neoadjuvant chemotherapy</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Breast cancer patients of vascular endocrine surgery department in Xijing Hospital
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HER2-negative breast cancer patients

          -  Without surgery

          -  Plans to neoadjuvant chemotherapy

        Exclusion Criteria:

          -  HER2-positive breast cancer patients

          -  Post-operative patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nanlin Li, Phd</last_name>
    <phone>+86-186-2963-7041</phone>
    <email>nanlin-74@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hongyu Xiao, Master</last_name>
    <phone>+86-186-2963-7040</phone>
    <email>louch2008@116.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xijing Hospital ï¼Œ Fourth Military Medical University</name>
      <address>
        <city>Xi`an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nanlin Li, Ph.D</last_name>
      <phone>+86-186-2963-7041</phone>
      <email>nanlin-74@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Hongyu Xiao, Master</last_name>
      <phone>+86-186-2963-7040</phone>
      <email>louch2008@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2012</study_first_submitted>
  <study_first_submitted_qc>July 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2012</study_first_posted>
  <last_update_submitted>July 25, 2012</last_update_submitted>
  <last_update_submitted_qc>July 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Xijing Hospital</investigator_affiliation>
    <investigator_full_name>LiNanlin,Ph.D, Chief Physician,Clinical Professor</investigator_full_name>
    <investigator_title>The department of Vascular endocrine surgery</investigator_title>
  </responsible_party>
  <keyword>bevacizumab</keyword>
  <keyword>neoadjuvant chemotherapy</keyword>
  <keyword>HER2-negative breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

